Return to homepagePandemic Pact

Next-generation mRNA vaccine against COVID-19 to provide long-term protection to the population within its national/international territories

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    BIRAC

  • Principal Investigator

    Ajay Singh

  • Research Location

    India

  • Lead Research Institution

    Gennova Biopharmaceuticals Ltd.

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Gennovas COVID-19 vaccine candidate - HGCO19, is a novel mRNA-based vaccine, using spike protein of the virus, reported to interact with host cells receptor, and lipid inorganic nanoparticle -LION used as a delivery system that has demonstrated safety, immunogenicity, neutralization antibody activity in the rodent and non-human primate models. Gennovas mRNA vaccine is based on a self-replicating mRNA platform, giving a dose-sparing advantage. This pandemic ready mRNA platform technology offers a rapid development path that will empower the nation to comb future pandemic outbreaks or any mutant form of the SARS-CoV-2 virus.